Bernardi S, Bossi F, Toffoli B, Giudici F, Bramante A, Furlanis G, Stenner E, Secchiero P, Zauli G, Carretta R, Fabris B. Association between thyroid hormones and TRAIL. Clin Biochem 2017;50(16-17):972-976.

Färkkilä A, Zauli G, Haltia U-M, Pihlajoki M, Unkila-Kallio L, Secchiero P, Heikinheimo M. Circulating levels of TNF-related apoptosis inducing-ligand are decreased in patients with large adult-type granulosa cell tumors-implications for therapeutic potential. Tumour Biol 2016;

Agnoletto C, Brunelli L, Melloni E, Pastorelli R, Casciano F, Rimondi E, Rigolin GMatteo, Cuneo A, Secchiero P, Zauli G. The anti-leukemic activity of sodium dichloroacetate in p53mutated/null cells is mediated by a p53-independent ILF3/p21 pathway. Oncotarget 2015;6(4):2385-96.

Biffi S, Voltan R, Rampazzo E, Prodi L, Zauli G, Secchiero P. Applications of nanoparticles in cancer medicine and beyond: optical and multimodal in vivo imaging, tissue targeting and drug delivery. Expert Opin Drug Deliv 2015;:1-13.

Trapella C, Voltan R, Melloni E, Tisato V, Celeghini C, Bianco S, Fantinati A, Salvadori S, Guerrini R, Secchiero P, Zauli G. Design, Synthesis, and Biological Characterization of Novel Mitochondria Targeted Dichloroacetate-Loaded Compounds with Antileukemic Activity. J Med Chem 2015;

Tisato V, Perri P, Rimondi E, Melloni E, Lamberti G, Milani D, Secchiero P, Zauli G. Kinetic Profiles of Inflammatory Mediators in the Conjunctival Sac Fluid of Patients upon Photorefractive Keratectomy. Mediators Inflamm 2015;2015:942948.

Tornese G, Tisato V, Monasta L, Brumatti LVecchi, Zauli G, Secchiero P. Serum TRAIL levels increase shortly after insulin therapy and metabolic stabilization in children with type 1 diabetes mellitus. Acta Diabetol 2015;52(5):1003-6.

Perri P, Zauli G, Gonelli A, Milani D, Celeghini C, Lamberti G, Secchiero P. TNF-related apoptosis inducing ligand in ocular cancers and ocular diabetic complications. Biomed Res Int 2015;2015:424019.

Bossi F, Bernardi S, Zauli G, Secchiero P, Fabris B. TRAIL modulates the immune system and protects against the development of diabetes. J Immunol Res 2015;2015:680749.

Cervellati C, Secchiero P, Bonaccorsi G, Celeghini C, Zauli G. Association of serum tumor necrosis factor-related apoptosis inducing ligand with body fat distribution as assessed by dual X-rays absorptiometry. Mediators Inflamm 2014;2014:306848.

Voltan R, Zauli G, Rizzo P, Fucili A, Pannella M, Marci R, Tisato V, Ferrari R, Secchiero P. In vitro endothelial cell proliferation assay reveals distinct levels of proangiogenic cytokines characterizing sera of healthy subjects and of patients with heart failure. Mediators Inflamm 2014;2014:257081.

Zauli G, Tisato V, Melloni E, Volpato S, Cervellati C, Bonaccorsi G, Radillo O, Marci R, Secchiero P. Inverse correlation between circulating levels of TNF-related apoptosis-inducing ligand and 17?-estradiol. J Clin Endocrinol Metab 2014;99(4):E659-64.

Celeghini C, Not T, Norcio A, Monasta L, Secchiero P. Levels of circulating TNF-related apoptosis-inducing ligand in celiac disease. Exp Ther Med 2014;8(6):1906-1908.

Tisato V, Zauli G, Gianesini S, Menegatti E, Brunelli L, Manfredini R, Zamboni P, Secchiero P. Modulation of circulating cytokine-chemokine profile in patients affected by chronic venous insufficiency undergoing surgical hemodynamic correction. J Immunol Res 2014;2014:473765.

Bernardi S, Fabris B, Thomas M, Toffoli B, Tikellis C, Candido R, Catena C, Mulatero P, Barbone F, Radillo O, Zauli G, Secchiero P. Osteoprotegerin increases in metabolic syndrome and promotes adipose tissue proinflammatory changes. Mol Cell Endocrinol 2014;394(1-2):13-20.

Athanasakis E, Melloni E, Rigolin GMatteo, Agnoletto C, Voltan R, Vozzi D, Piscianz E, Segat L, dal Monego S, Cuneo A, Secchiero P, Zauli G. The p53 transcriptional pathway is preserved in ATMmutated and NOTCH1mutated chronic lymphocytic leukemias. Oncotarget 2014;5(24):12635-45.

Agnoletto C, Melloni E, Casciano F, Rigolin GMatteo, Rimondi E, Celeghini C, Brunelli L, Cuneo A, Secchiero P, Zauli G. Sodium dichloroacetate exhibits anti-leukemic activity in B-chronic lymphocytic leukemia (B-CLL) and synergizes with the p53 activator Nutlin-3. Oncotarget 2014;5(12):4347-60.

Zauli G, Celeghini C, Monasta L, Martinelli M, Luppi S, Gonelli A, Grill V, Ricci G, Secchiero P. Soluble TRAIL is present at high concentrations in seminal plasma and promotes spermatozoa survival. Reproduction 2014;148(2):191-8.

Davanzo R, Zauli G, Monasta L, Brumatti LVecchi, Abate MValentina, Ventura G, Rimondi E, Secchiero P, Demarini S. Human colostrum and breast milk contain high levels of TNF-related apoptosis-inducing ligand (TRAIL). J Hum Lact 2013;29(1):23-5.

Tisato V, Toffoli B, Monasta L, Bernardi S, Candido R, Zauli G, Secchiero P. Patients affected by metabolic syndrome show decreased levels of circulating platelet derived growth factor (PDGF)-BB. Clin Nutr 2013;32(2):259-64.

Secchiero P, Rimondi E, di Iasio MGrazia, Voltan R, Gonelli A, Zauli G. Activation of the p53 pathway induces ?-smooth muscle actin expression in both myeloid leukemic cells and normal macrophages. J Cell Physiol 2012;227(5):1829-37.

Bosco R, Rabusin M, Voltan R, Celeghini C, Corallini F, Capitani S, Secchiero P. Anti-leukemic activity of dasatinib in both p53(wild-type) and p53(mutated) B malignant cells. Invest New Drugs 2012;30(1):417-22.

Tisato V, Zauli G, Voltan R, Gianesini S, di Iasio MGrazia, Volpi I, Fiorentini G, Zamboni P, Secchiero P. Endothelial cells obtained from patients affected by chronic venous disease exhibit a pro-inflammatory phenotype. PLoS One 2012;7(6):e39543.

Biolo G, Secchiero P, De Giorgi S, Tisato V, Zauli G. The energy balance positively regulates the levels of circulating TNF-related apoptosis inducing ligand in humans. Clin Nutr 2012;31(6):1018-21.

Rimondi E, di Iasio MGrazia, Gonelli A, Celeghini C, Secchiero P, Zauli G. Hydrogen sulfide down-regulates the expression and release of osteoprotegerin (OPG) by vascular endothelial cells. Invest New Drugs 2012;30(4):1731-5.

Zauli G, Corallini F, Zorzet S, Grill V, Marzari R, Secchiero P. In vivo anti-lymphoma activity of an agonistic human recombinant anti-TRAIL-R2 minibody. Invest New Drugs 2012;30(1):405-7.

Comar M, Secchiero P, De Lorenzo E, Martelossi S, Tommasini A, Zauli G. JCV+ Patients with Inflammatory bowel disease show elevated plasma levels of MIG and SCF. Inflamm Bowel Dis 2012;18(6):1194-6.

Secchiero P, Melloni E, Voltan R, Norcio A, Celeghini C, Zauli G. MCL1 down-regulation plays a critical role in mediating the higher anti-leukaemic activity of the multi-kinase inhibitor Sorafenib with respect to Dasatinib. Br J Haematol 2012;157(4):510-4.

Comar M, Cuneo A, Maestri I, Melloni E, Pozzato G, Soffritti O, Secchiero P, Zauli G. Merkel-cell polyomavirus (MCPyV) is rarely associated to B-chronic lymphocytic leukemia (1 out of 50) samples and occurs late in the natural history of the disease. J Clin Virol 2012;55(4):367-9.

Secchiero P, Corallini F, Zavan B, Tripodo C, Vindigni V, Zauli G. Mesenchymal stem cells display hepato-protective activity in lymphoma bearing xenografts. Invest New Drugs 2012;30(2):803-7.

Carinci F, Monasta L, Rubini C, Stramazzotti D, Palmieri A, Melloni E, Knowles A, Ronfani L, Zauli G, Secchiero P. The negative prognostic value of TRAIL overexpression in oral squamous cell carcinomas does not preclude the potential therapeutic use of recombinant TRAIL. Invest New Drugs 2012;30(2):810-8.

Gonelli A, Radillo O, Drioli S, Rimondi E, Secchiero P, Bonora GMaria. Pegylated TRAIL retains anti-leukemic cytotoxicity and exhibits improved signal transduction activity with respect to TRAIL. Invest New Drugs 2012;30(2):828-32.

Bernardi S, Norcio A, Toffoli B, Zauli G, Secchiero P. Potential role of TRAIL in the management of autoimmune diabetes mellitus. Curr Pharm Des 2012;18(35):5759-65.

Tisato V, Monasta L, Biolo G, Donatelli F, Secchiero P, Zauli G. Simultaneous determination of multiple cytokines reveals a pro-inflammatory and pro-angiogenic signature after major cardiothoracic surgery: potential role of C-reactive protein. Cytokine 2012;60(3):593-5.

Agostinis C, Bulla R, Tisato V, De Seta F, Alberico S, Secchiero P, Zauli G. Soluble TRAIL is elevated in recurrent miscarriage and inhibits the in vitro adhesion and migration of HTR8 trophoblastic cells. Hum Reprod 2012;27(10):2941-7.

Zauli G, Celeghini C, Melloni E, Voltan R, Ongari M, Tiribelli M, di Iasio MGrazia, Lanza F, Secchiero P. The sorafenib plus nutlin-3 combination promotes synergistic cytotoxicity in acute myeloid leukemic cells irrespectively of FLT3 and p53 status. Haematologica 2012;97(11):1722-30.

Bernardi S, Secchiero P, Zauli G. State of art and recent developments of anti-cancer strategies based on TRAIL. Recent Pat Anticancer Drug Discov 2012;7(2):207-17.

Bernardi S, Zauli G, Tikellis C, Candido R, Fabris B, Secchiero P, Cooper ME, Thomas MC. TNF-related apoptosis-inducing ligand significantly attenuates metabolic abnormalities in high-fat-fed mice reducing adiposity and systemic inflammation. Clin Sci (Lond) 2012;123(9):547-55.

Secchiero P, Zauli G. TRAIL, a new weapon against neointimal hyperplasia. Cardiology 2012;123(2):94-6.

Marcuzzi A, Secchiero P, Crovella S, Zauli G. TRAIL administration down-modulated the acute systemic inflammatory response induced in a mouse model by muramyldipeptide or lipopolysaccharide. Cytokine 2012;60(1):43-6.

Bernardi S, Milani D, Fabris B, Secchiero P, Zauli G. TRAIL as biomarker and potential therapeutic tool for cardiovascular diseases. Curr Drug Targets 2012;13(9):1215-21.

Toffoli B, Bernardi S, Candido R, Zacchigna S, Fabris B, Secchiero P. TRAIL shows potential cardioprotective activity. Invest New Drugs 2012;30(3):1257-60.

Volpato S, Ferrucci L, Secchiero P, Corallini F, Zuliani G, Fellin R, Guralnik JM, Bandinelli S, Zauli G. Association of tumor necrosis factor-related apoptosis-inducing ligand with total and cardiovascular mortality in older adults. Atherosclerosis 2011;215(2):452-8.

Zauli G, Monasta L, Rimondi E, Brumatti LVecchi, Radillo O, Ronfani L, Montico M, D'Ottavio G, Alberico S, Secchiero P. Circulating TRAIL shows a significant post-partum decline associated to stressful conditions. PLoS One 2011;6(12):e27011.

Zauli G, Voltan R, Bosco R, Melloni E, Marmiroli S, Rigolin GMatteo, Cuneo A, Secchiero P. Dasatinib plus Nutlin-3 shows synergistic antileukemic activity in both p53 wild-type and p53 mutated B chronic lymphocytic leukemias by inhibiting the Akt pathway. Clin Cancer Res 2011;17(4):762-70.

Zauli G, Voltan R, di Iasio MGrazia, Bosco R, Melloni E, Sana MElena, Secchiero P. miR-34a induces the downregulation of both E2F1 and B-Myb oncogenes in leukemic cells. Clin Cancer Res 2011;17(9):2712-24.

Zauli G, Bosco R, Secchiero P. Molecular targets for selective killing of TRAIL-resistant leukemic cells. Expert Opin Ther Targets 2011;15(8):931-42.

Toffoli B, Bernardi S, Candido R, Sabato N, Carretta R, Corallini F, Secchiero P, Zauli G, Fabris B. Osteoprotegerin induces morphological and functional alterations in mouse pancreatic islets. Mol Cell Endocrinol 2011;331(1):136-42.

Toffoli B, Pickering RJ, Tsorotes D, Wang B, Bernardi S, Kantharidis P, Fabris B, Zauli G, Secchiero P, Thomas MC. Osteoprotegerin promotes vascular fibrosis via a TGF-?1 autocrine loop. Atherosclerosis 2011;218(1):61-8.

Secchiero P, Bosco R, Celeghini C, Zauli G. Recent advances in the therapeutic perspectives of Nutlin-3. Curr Pharm Des 2011;17(6):569-77.

Corallini F, Celeghini C, Rimondi E, di Iasio MGrazia, Gonelli A, Secchiero P, Zauli G. Trail down-regulates the release of osteoprotegerin (OPG) by primary stromal cells. J Cell Physiol 2011;226(9):2279-86.

Corallini F, Secchiero P, Castellino G, Montecucco M, Trotta F, Zauli G. Circulating levels of frizzled-related protein (FRZB) are increased in patients with early rheumatoid arthritis and decrease in response to disease-modifying antirheumatic drugs. Ann Rheum Dis 2010;69(9):1733-4.

Zauli G, Toffoli B, di Iasio MGrazia, Celeghini C, Fabris B, Secchiero P. Treatment with recombinant tumor necrosis factor-related apoptosis-inducing ligand alleviates the severity of streptozotocin-induced diabetes. Diabetes 2010;59(5):1261-5.